Skip to main content
TipRanks
Go Ultimate75% OFF

4basebio UK Societas (88Q) Stock Price & Analysis

0 Followers

88Q Stock Chart & Stats

€5.85€0.00(0.00%)
At close: 5:30 PM GMT+1
€5€5.5€6€6.5Aug 31Sep 9Sep 29Oct 16Oct 26Nov 10
Day’s Range
EUR 5.70 - EUR 5.85
52-Week Range
EUR 4.64 - EUR 9.50
Previous Close
EUR 5.85
Volume
N/A
Average Volume (3M)
149
Market Cap
EUR 120.70M
Enterprise Value
EUR 89.85M
Total Cash (Recent Filing)
EUR 14.05M
Total Debt (Recent Filing)
EUR 23.10M
Price to Earnings (P/E)
―
Beta
0.23
Next Earnings
Jun 02, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Synthetic DNA Positioning

The company is positioned in a specialized enabling segment of biotechnology, supplying synthetic DNA and related capabilities for gene therapies, vaccines, and genetic medicines. This focus gives the business a clear role in supporting biopharma development and manufacturing workflows over the medium term.

Long-term Revenue Expansion

Despite a decline in 2025, the company has expanded revenue over the 2020–2025 period and reports an 81.46% revenue-growth metric. Growth from a small base indicates that its products and capabilities have achieved some commercial scaling, supporting future operating leverage if expansion resumes.

Positive Gross Margin

Positive gross margin indicates that 4basebio captures value above direct production costs, providing an underlying economic contribution from its offerings. Although volatility and high operating costs currently prevent profitability, this gross-profit base could support improved earnings if revenue scales or expenses become more efficient.

Bears Say

Persistent And Widening Losses

The combination of declining 2025 revenue and materially wider losses shows that the business has not yet converted its technology and revenue base into sustainable profitability. Negative operating and net margins leave limited internal funding capacity and make earnings improvement dependent on renewed growth or cost control.

Accelerating Cash Burn

Persistent negative operating and free cash flow means the company is consuming cash rather than self-funding operations. The acceleration in 2025 increases the importance of revenue scaling, expense reductions, or external financing, and can constrain investment in product development and manufacturing capabilities.

Deteriorating Balance Sheet

Higher debt alongside sharply lower equity weakens financial flexibility and increases the burden placed on a loss-making business. Declining assets and elevated debt-to-equity can restrict capital-allocation options, while continued losses could increase dilution or funding pressure if external capital is required.

4basebio UK Societas News

88Q FAQ

What was 4basebio UK Societas’s price range in the past 12 months?
4basebio UK Societas lowest stock price was €4.64 and its highest was €9.50 in the past 12 months.
What is 4basebio UK Societas’s market cap?
4basebio UK Societas’s market cap is €120.70M.
When is 4basebio UK Societas’s upcoming earnings report date?
4basebio UK Societas’s next earnings report is estimated for Jun 02, 2027 (not yet confirmed), which is in 199 days.
How were 4basebio UK Societas’s earnings last quarter?
4basebio UK Societas released its earnings results on Sep 25, 2026. The company reported -€0.674 earnings per share for the quarter.
Is 4basebio UK Societas overvalued?
According to Wall Street analysts 4basebio UK Societas’s price is currently Undervalued.
Does 4basebio UK Societas pay dividends?
4basebio UK Societas does not currently pay dividends.
What is 4basebio UK Societas’s EPS estimate?
4basebio UK Societas’s EPS estimate is -0.70.
How many shares outstanding does 4basebio UK Societas have?
4basebio UK Societas has 19,234,728 shares outstanding.
What happened to 4basebio UK Societas’s price movement after its last earnings report?
4basebio UK Societas reported an EPS of -€0.674 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of 4basebio UK Societas?
Currently, no hedge funds are holding shares in DE:88Q
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology